USANA Health Sciences - USNA Stock Forecast, Price & News

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Jefferies Financial Group lowered USANA Health Sciences from a "hold" rating to an "underperform" rating and decreased their target price for the stock from $78.00 to $53.00 in a research report on Thursday, July 7th. StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 26th. Finally, DA Davidson reduced their price target on shares of USANA Health Sciences to $57.00 and set an "outperform" rating for the company in a research report on Wednesday, July 27th. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. According to data from MarketBeat, USANA Health Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $77.33.

USANA Health Sciences Stock Up 0.8 %

NYSE:USNA opened at $72.78 on Friday. USANA Health Sciences has a 52 week low of $63.49 and a 52 week high of $103.95. The firm has a market capitalization of $1.40 billion, a P/E ratio of 16.03 and a beta of 0.72. The company has a 50-day moving average price of $70.41 and a 200-day moving average price of $76.77.

USANA Health Sciences (NYSE:USNA - Get Rating) last released its earnings results on Tuesday, July 26th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.05). USANA Health Sciences had a return on equity of 22.49% and a net margin of 8.27%. During the same quarter in the previous year, the business earned $1.87 earnings per share. As a group, equities research analysts anticipate that USANA Health Sciences will post 3.98 EPS for the current year.

Insider Buying and Selling

In other USANA Health Sciences news, insider Paul A. Jones sold 5,029 shares of the company's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $70.00, for a total value of $352,030.00. Following the completion of the transaction, the insider now directly owns 3,682 shares in the company, valued at approximately $257,740. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other USANA Health Sciences news, insider Paul A. Jones sold 5,029 shares of the company's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $70.00, for a total value of $352,030.00. Following the completion of the transaction, the insider now directly owns 3,682 shares in the company, valued at approximately $257,740. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brent Neidig sold 1,400 shares of the company's stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $70.93, for a total value of $99,302.00. Following the completion of the transaction, the insider now owns 1,406 shares of the company's stock, valued at $99,727.58. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,919 shares of company stock valued at $556,186. 0.36% of the stock is owned by corporate insiders.